HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
WORX
SCWorx Corp.
There isn't enough reported data to score WORX yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
WORX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
WORX's revenue is currently stable, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
WORX PE Valuation
WORX has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
WORX Forward outlook
There aren't enough analyst estimates for WORX to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
WORX has the stronger earnings trend. Trailing diluted EPS is down 257% for HIMS versus WORX down 131%.
WORX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$174.60 | +$397.80 |
| Q2 2025 | -$196.20 | +$462.60 |
| Q1 2025 | -$160.20 | +$478.80 |
| Q4 2024 | -$140.40 | +$554.40 |
| Q3 2024 | -$572.40 | -$302.40 |
| Q2 2024 | -$658.80 | -$442.80 |
| Q1 2024 | -$639.00 | -$315.00 |
| Q4 2023 | -$694.80 | -$289.80 |
WORX is still losing money, but far less than before: $174.60 per share over the past year, against $972.00 at its worst in late 2021.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over WORX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over WORX on profitability, with a higher operating margin.
WORX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $706K | +3.4% |
| Q1 2026 | $744.9K | +3.4% |
| Q4 2025 | $768.9K | +14% |
| Q3 2025 | $705.8K | -7.1% |
| Q2 2025 | $682.6K | -8% |
| Q1 2025 | $720.3K | -11% |
| Q4 2024 | $675.7K | -26% |
| Q3 2024 | $759.7K | -16% |
WORX's revenue fell from its 2019 peak and has held roughly level since: $706,049 last quarter, up 3.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -17% | +26 points |
| Q1 2026 | -18% | +28 points |
| Q4 2025 | -25% | +31 points |
| Q3 2025 | -20% | +32 points |
| Q2 2025 | -43% | -1.6 points |
| Q1 2025 | -46% | -24 points |
| Q4 2024 | -56% | -51 points |
| Q3 2024 | -52% | +43 points |
WORX's operating margin was −17% last quarter, up 26 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
WORX has the stronger cash trend. Its trailing FCF is down 25% versus its history, compared with HIMS at down 84%.
WORX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$5.7K | +$646.1K |
| Q1 2026 | -$252.7K | +$151.9K |
| Q3 2025 | -$358.1K | +$4.5K |
| Q2 2025 | -$651.8K | -$124.1K |
| Q1 2025 | -$404.6K | -$345.1K |
| Q4 2024 | -$134.4K | -$29.6K |
| Q3 2024 | -$362.6K | +$10.2K |
| Q2 2024 | -$527.8K | -$180K |
WORX has burned cash in almost every quarter: −$1M over the past year, against −$1M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over WORX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
WORX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1% | +852 shares |
| 1 year | +735% | +78.6K shares |
| 3 years | +1897% | +84.8K shares |
| 5 years | +2406% | +85.7K shares |
WORX has 89,269 diluted shares, up 735% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
WORX Net Leverage
WORX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
WORX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.5 | Neutral |
| Stochastic | 4.1 | Oversold |
WORX's weekly RSI is 36 (neutral) and its Stochastic is 4 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
WORX PE vs Healthcare Sector
WORX has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
WORX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.39 | 47% below |
| 20 week MA | $4.13 | 69% below |
| 50 week MA | $19.4 | 93% below |
| 100 week MA | $80.5 | 98% below |
| 200 week MA | $313.5 | 100% below |
WORX is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over WORX on returns for 2026, with the stronger performance.
WORX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7,722.0 | $4,104.0 | -47% |
| 2021 | $4,104.0 | $3,699.0 | -9.9% |
| 2022 | $3,699.0 | $1,107.0 | -70% |
| 2023 | $1,107.0 | $331.2 | -70% |
| 2024 | $331.2 | $302.4 | -8.7% |
| 2025 | $302.4 | $37.8 | -88% |
| 2026 YTD | $37.8 | $1.27 | -97% |
WORX has finished every year since 2020 lower, and it's down 97% so far in 2026.